Intensity Therapeutics (INTS) Assets (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Assets came in at $12.3 million in Q1 2026, up 301.01% YoY from $3.1 million in Q1 2025, and down 12.84% on a QoQ basis from $14.1 million in Q4 2025.
Intensity Therapeutics (INTS) Assets (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Assets data on file, last reported at $12.3 million in Q1 2026.
- Quarterly Assets rose 301.01% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (up 301.01% YoY) and the FY2025 annual result came in at $14.1 million, up 194.81% from the prior year.
- Assets fell to $12.3 million in Q1 2026, from $14.1 million in the prior quarter.
- In the past five years, Assets ranged from a high of $18.2 million in Q2 2023 to a low of $1.8 million in Q4 2022.
- A 5-year average of $9.9 million and a median of $9.6 million in 2025 frame the typical range for Assets.
- Annual changes were most pronounced in 2023 — Assets jumped 884.35% — and 2025, when it sank 75.3%.
- Tracing INTS's Assets over 5 years: stood at $1.8 million in 2022, then jumped by 884.35% to $17.3 million in 2023, then slumped by 72.34% to $4.8 million in 2024, then soared by 194.81% to $14.1 million in 2025, then slipped by 12.84% to $12.3 million in 2026.
- The last three Assets figures came in at $12.3 million (Q1 2026), $14.1 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Intensity Therapeutics | 12.99 Mn | 12.99 Mn | - | 11.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.52 Mn |
| Mar 31, 2026 | 12.29 Mn |
| Dec 31, 2025 | 14.10 Mn |
| Sep 30, 2025 | 9.59 Mn |
| Jun 30, 2025 | 4.44 Mn |
| Mar 31, 2025 | 3.07 Mn |
| Dec 31, 2024 | 4.78 Mn |
| Sep 30, 2024 | 5.21 Mn |
| Jun 30, 2024 | 8.67 Mn |
| Mar 31, 2024 | 12.41 Mn |
| Dec 31, 2023 | 17.30 Mn |
| Sep 30, 2023 | 16.82 Mn |
| Jun 30, 2023 | 18.23 Mn |
| Dec 31, 2022 | 1.76 Mn |